Medicare Negotiation and Competitive Licensing Act of 2019
- Last Action
- 9/25/2019
Actions
- 2019-09-25Subcommittee Hearings Held.
- 2019-02-08Referred to the Subcommittee on Health.
- 2019-02-07Referred to the Subcommittee on Health.
- 2019-02-07Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2019-02-07Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2019-02-07Introduced in House
- 2019-02-07Introduced in House
CRS Summary
As of 2019-02-07 (00)
Medicare Negotiation and Competitive Licensing Act of 2019
This bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. (Current law prohibits the CMS from doing so.)
The CMS must take certain factors into account during negotiations, including the clinical- and cost-effectiveness of the drug, the financial burden on patients, and unmet patient needs. If the CMS is unable to negotiate the price of a drug, such drug is subject to competitive licensing in order to further its sale under Medicare, notwithstanding existing government-granted exclusivities.
Additionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).
Cosponsors (20)
- Peter Welch (D-VT)
- ELIJAH CUMMINGS (D-MD)
- Alma Adams (D-NC)
- Karen Bass (D-CA)
- Joyce Beatty (D-OH)
- EARL BLUMENAUER (D-OR)
- Suzanne Bonamici (D-OR)
- Matt Cartwright (D-PA)
- Ed Case (D-HI)
- Sean Casten (D-IL)
- Kathy Castor (D-FL)
- Joaquin Castro (D-TX)
- Judy Chu (D-CA)
- David Cicilline (D-RI)
- Gilbert Cisneros (D-CA)
- WM. CLAY (D-MO)
- Emanuel Cleaver (D-MO)
- Steve Cohen (D-TN)
- Joe Courtney (D-CT)
- Charlie Crist (D-FL)
Subjects
- Competition and antitrust
- Drug safety, medical device, and laboratory regulation
- Health care costs and insurance
- Inflation and prices
- Licensing and registrations
- Manufacturing
- Medicare
- Prescription drugs
- Product safety and quality
- Public contracts and procurement
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.